Navigation Links
LSUHSC awarded $2 million dollar grant to prevent pneumonia linked to immune deficiency
Date:7/13/2010

New Orleans, LA Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia (PCP), which can be a complication of HIV/AIDS. It can also be a complication of cancer, organ or bone marrow transplantation, as well as the chronic use of corticosteroids or other medications that affect the immune system.

Pneumocystis carinii pneumonia remains an important clinical problem and although there is a well-known relationship between CD4 cell count and the risk of Pneumocystis carinii infection, defense mechanisms against it are not fully understood. Dr. Kolls and his research team will study the role of a subset of CD4 cells which he believes are missing in Pneumocystis carinii infection and which when restored, produce an effective immune response to the infection. These are the T-helper cells, Th1, Th2, and Th17. The research funded under this grant will determine the role of interleukin-23 and interleukin-12 in regulating Th1 immunity to Pneumocystis carinii, and the team hopes to show that by vaccinating genetically engineered mice with CD4+ T-cells belonging to any of these T-cell subsets, immunity will be sufficient to protect against PCP.

"This research will define the types of T-cells that are needed to prevent this life-threatening infection," notes Dr. Kolls. "It is our hope that vaccines can activate these cells to prevent or treat PCP."

According to the Centers for Disease Control and Prevention, Pneumocystis pneumonia (PCP), which is caused by Pneumocystis jirovecii (formerly P. carinii), is frequently the first serious illness encountered by HIV-infected persons. During the early years of the AIDS epidemic, PCP was the AIDS-defining illness for as many as two thirds of patients in the United States. Although a decline in incidence of PCP occurred during the era of highly active antiretroviral therapy (HAART), PCP remains the most common serious opportunistic illness in HIV-infected persons. Patients in the developing world without access to PCP prophylaxis or antiretroviral drugs remain at high risk, and PCP continues to develop in certain groups in industrialized countries. There is also a potential for drug resistance to develop.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC awarded patent for compound inhibiting cancer and other diseases
2. LSUHSC research identifies key contributor to Alzheimers disease process
3. LSUHSC student awarded top national honor for diabetes research
4. LSUHSC public health researcher finds reason for weight gain
5. LSUHSC research describes function of key protein in cancer spread
6. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
7. LSUHSC research helps link schizophrenia to specific DNA region
8. LSUHSCs Bazan awarded ARRA grant to preserve vision
9. LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
10. Grant supports LSUHSC research on how like cell receptor systems determine very different functions
11. LSUHSC researchers working to prevent diabetic neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology: